Valuation: Sera Prognostics, Inc.

Market Cap 78.32M 68.43M 62.84M 58.6M 111M 7.46B 113M 757M 293M 3.66B 294M 288M 12.6B P/E 2026 *
-3.05x
P/E 2027 * -3.57x
Enterprise Value 78.32M 68.43M 62.84M 58.6M 111M 7.46B 113M 757M 293M 3.66B 294M 288M 12.6B EV / Sales 2026 *
216x
EV / Sales 2027 * 29.3x
Free-Float
86.29%
Yield 2026 *
-
Yield 2027 * -
1 day-1.48%
1 week+11.11%
Current month+9.89%
1 month-1.96%
3 months-0.50%
6 months-33.33%
Current year-32.20%
1 week 1.76
Extreme 1.765
2.09
1 month 1.72
Extreme 1.725
2.33
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
15.5
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 01/06/2023
Director of Finance/CFO 39 07/06/2023
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 74 20/04/2011
Chairman 58 08/06/2023
Director/Board Member 59 01/11/2011
Date Insider Type Main position Quantity % Market Cap.
06-11Sell

General Counsel

-2,179 0.0057%
06-11Sell

Chief Technology Officer

-362 0.0009%
06-11Sell

Chief Financial Officer

-2,037 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
-1.48%+11.11%-18.37%-39.30% 78.32M
+1.18%+1.99%+14.39%+12.90% 23.26B
-0.70%+1.21%+36.86% - 19.55B
-2.90%+2.68%+89.24%+56.99% 3.78B
-1.47%-0.64%+21.21%-27.90% 3.51B
-4.05%+3.52%+244.06%+238.05% 2.69B
+1.83%+5.11%+265.10%+344.04% 2.1B
+1.38%-0.98%-28.36% - 1.8B
+2.87%+4.41%-29.59%-39.27% 1.8B
+1.49%+3.69%+9.39%-4.93% 1.7B
Average -0.21%+4.15%+60.39%+67.57% 6.03B
Weighted average by Cap. -0.07%+1.30%+43.00%+43.67%

Financials

2026 *2027 *
Net sales 362K 317K 291K 271K 514K 34.51M 523K 3.5M 1.36M 16.93M 1.36M 1.33M 58.33M 2.68M 2.34M 2.15M 2M 3.79M 255M 3.86M 25.84M 10.02M 125M 10.04M 9.83M 430M
Net income -33.26M -29.06M -26.69M -24.89M -47.18M -3.17B -47.98M -321M -125M -1.55B -125M -122M -5.35B -29.98M -26.2M -24.06M -22.43M -42.53M -2.85B -43.25M -290M -112M -1.4B -113M -110M -4.82B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
02/07/26 $2.000 -1.48% 25,951
01/07/26 $2.030 +11.54% 24,333
30/06/26 $1.820 +0.55% 39,882
29/06/26 $1.810 +0.56% 12,190
26/06/26 $1.800 0.00% 46,311
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.000USD
Average target price
5.500USD
Spread / Average Target
+175.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock